\
&
Contact us
\
&
Contact us
Published on | 4 years ago
ProgrammesThe Commission has updated on 30 November 2021 the pre-draft of the Annotated Model Grant Agreement (of all programmes, not only Horizon Europe).
This version has been updated with corporate annotations of Articles 1-6 (i.e. annotations for all programmes). These annotations explain notably personnel costs daily rate calculation with single calculation over the reporting period.
The annotations to the other articles remain those of the pre-draft AGA for HE as previously published on 23 July 2021. These will be updated later on by further batch(es) of corporate annotations for all programmes. We will keep you informed about this process.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health EIT AI Continent Deployment: Best use of technologies
EIT Health’s Innovation Uptake Call focuses on mature digital, data-driven and AI-powered solutions and seeks to support the last steps towards commercialisation. Applicants must apply as a consortium of at least two independent legal entities from different countries. The consortium must include partners from at least two sides of the Knowl... read more
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
